Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;20(9):505-506.
doi: 10.1038/s41574-024-01006-7.

Metabolic alliance: pharmacotherapy and exercise management of obesity

Javier Butragueño  1 , Jonatan R Ruiz  2   3   4
Affiliations

Metabolic alliance: pharmacotherapy and exercise management of obesity

Javier Butragueño et al. Nat Rev Endocrinol. 2024 Sep.
No abstract available

PubMed Disclaimer

References

    1. Jensen, S. B. K. et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine 69, 102475 (2024). - DOI - PubMed - PMC
    1. Ansari, S., Khoo, B. & Tan, T. Targeting the incretin system in obesity and type 2 diabetes mellitus. Nat. Rev. Endocrinol. https://doi.org/10.1038/s41574-024-00979-9 (2024). - DOI - PubMed
    1. Jastreboff, A. M. et al. Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New Eng. J. Med. 389, 514–526 (2023). - DOI - PubMed
    1. Jensen, S. B. K. et al. Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function. Obesity 31, 977–989 (2023). - DOI - PubMed
    1. Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New Eng. J. of Med. 389, 2221–2232 (2023). - DOI

Substances

LinkOut - more resources